Fierce Pharma
OCTOBER 3, 2024
Hot on the tail of AstraZeneca’s Imfinzi, Bristol Myers Squibb’s PD-1/L1 inhibitor Opdivo has expanded its non-small cell lung cancer (NSCLC) net with an
MedCity News
OCTOBER 3, 2024
More investors are becoming interested in digital health startups specifically targeting youth behavioral health. However, there are still more opportunities to reach youth on Medicaid. The post Funding In Youth Mental Health Is Growing. Where are the Opportunities? appeared first on MedCity News.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Fierce Pharma
OCTOBER 3, 2024
Eli Lilly’s juggernaut diabetes and obesity drugs Mounjaro and Zepbound have been erased from the FDA’s shortage list, | Eli Lilly’s juggernaut diabetes and obesity drugs Mounjaro and Zepbound have been erased from the FDA’s shortage list, freeing the company from competing with compounding pharmacies that have been producing copycat versions of the in-demand treatments.
MedCity News
OCTOBER 3, 2024
Laboratory construction has waned in the past two years due to the end of the pandemic and an economic slowdown, according to a new report from CBRE. The firm predicts in-progress lab construction will decline to pre-pandemic levels by 2026. The post CBRE Report: Post-Pandemic Slowdown Now Evident in Oversupply of Biotech Labs appeared first on MedCity News.
Advertisement
Quotas need to be hit. Revenue goals need to be met. This reality makes shortening sales onboarding time a top priority. Organizations with a standard onboarding process boost employee retention by 58% and increase productivity by 50%. Unfortunately, many companies struggle with inefficient processes that lead to high turnover and missed revenue opportunities.
Fierce Pharma
OCTOBER 3, 2024
As officials consider how to distribute Eli Lilly’s Mounjaro to a nation that has a rapidly growing (PDF) o | As officials consider how to distribute Eli Lilly’s Mounjaro to a nation that has a rapidly growing obesity problem, England’s National Health Service is proposing that those who need it most should get it first.
MedCity News
OCTOBER 3, 2024
Providers should incorporate mental health screenings as a standard part of cancer care for patients and their loved ones. The post Shock, Fear and Anxiety – The Complexity of Breast Cancer Beyond Diagnosis appeared first on MedCity News.
Pharma Rep Focus brings together the best content for pharma rep professionals from the widest variety of industry thought leaders.
MedCity News
OCTOBER 3, 2024
The Hippocratic oath can’t stop with direct patient care; the healthcare industry and its key stakeholders must address persistent public health problems systematically. We have the tools to reduce medication harm by half or more; it is long past time to make this a public health priority. The post First Do No Harm: Support Legislative Efforts to Combat the Adverse Drug Event Epidemic appeared first on MedCity News.
Fierce Pharma
OCTOBER 3, 2024
Armed with what it sees as impressive clinical data and bolstered by long-standing ties to the Niemann-Pick disease type C (NPC) community, Zevra Therapeutics is confident that its new drug Miplyff | Armed with what it sees as impressive clinical data and bolstered by long-standing ties to the Niemann-Pick disease type C community, Zevra Therapeutics is confident that its new drug Miplyffa can become the “foundation and the cornerstone” for treatment of the debilitating rare disease going forwar
Pharmaceutical Technology
OCTOBER 3, 2024
GLP-1 RAs are being recommended on social media, raising questions about who can see the content and what the effects might be.
Fierce Pharma
OCTOBER 3, 2024
As the BIOSECURE Act works its way through the U.S. legislative branch, two companies named in the bill are reportedly weighing sales of certain units and facilities. | WuXi AppTec has put its cell and gene therapy manufacturing arm, WuXi Advanced Therapies, on the market, The Financial Times reported Thursday. At the same time, WuXi Biologics is working with advisors to gauge interest in some of its European production facilities, the news outlet added, citing sources.
MedCity News
OCTOBER 3, 2024
AI startups should be thoughtful about which healthcare market(s) they’re going after, according to investors at Bessemer Venture Partners. Healthcare AI startups seeking venture capital face heightened expectations for scale, which requires access to substantial total addressable markets. The post How Can AI Startups Navigate Healthcare’s Fragmented Landscape?
Fierce Pharma
OCTOBER 3, 2024
After unlocking commercial supply and enlisting a manufacturing partner earlier this year, Ferring Pharmaceuticals has reached a new turning point on its quest to satisfy current and future demand | Ferring on Thursday opened a new global manufacturing hub in Kuopio, Finland, to help produce drug substance for Adstiladrin, which was approved by the FDA in late 2022 as the first gene therapy to target high-risk and non-muscle invasive bladder cancer in patients who no longer respond to therapy.
pharmaphorum
OCTOBER 3, 2024
Gilead has partnered with six generic manufacturers to expand access to HIV Drug lenacapavir in high-incidence, resource-limited countries following promising clinical trial results.
Fierce Pharma
OCTOBER 3, 2024
On the same day as Roche's Pharma Day in London, the biopharma giant revealed a high-dollar deal with Chinese-American biotech Regor for the latter's CDK inhibitors. | On the same day as Roche's Pharma Day in London, the drugs giant struck a high-dollar deal with Chinese-American biotech Regor for the latter's CDK inhibitors. Legend's momentum continued with a strong survival showing for Johnson & Johnson-partnered Carvykti and the announcement of a planned R&D f
Advertisement
Clinical trial data management is increasingly challenging as studies grow in complexity. Quickly accessing and analyzing study data is vital for assessing trial progress and patient safety. In this paper, we explore real-time data access and analysis for proactive study management. We investigate using adverse event (AE) data to monitor safety and discuss a clinical analytics platform that supports collaboration and data review workflows.
pharmaphorum
OCTOBER 3, 2024
Proscia announces launch of Concentriq Embeddings and Proscia AI Toolkit, hoping to accelerate precision medicine R&D.
European Pharmaceutical Review
OCTOBER 3, 2024
Ferring Pharmaceuticals has opened a new European manufacturing site focused on supporting production for one of its gene therapies to treat non-muscle invasive bladder cancer (NMIBC). The global manufacturing hub in Kuopio, Finland will bolster supply of the drug substance of its gene therapy Adstiladrin ® (nadofaragene firadenovec-vncg). The treatment is the first and only US Food and Drug Administration (FDA)-approved intravesical non-replicating gene therapy for adults with high-risk Bacillu
PharmaTimes
OCTOBER 3, 2024
Phase 1 trial of IRL757 demonstrates good absorption and safety profile
pharmaphorum
OCTOBER 3, 2024
A new report commissioned by ABPI found hospitals engaging in industry partnerships more likely to follow NICE recommendations.
Advertiser: ZoomInfo
Marketing technology is essential for B2B marketers to stay competitive in a rapidly changing digital landscape — and with 53% of marketers experiencing legacy technology issues and limitations, they’re researching innovations to expand and refine their technology stacks. To help practitioners keep up with the rapidly evolving martech landscape, this special report will discuss: How practitioners are integrating technologies and systems to encourage information-sharing between departments and pr
PharmaTimes
OCTOBER 3, 2024
Largest real-world study demonstrates significant survival advantage
PharmaTech
OCTOBER 3, 2024
This Behind the Headlines news roundup panel discussion on recent news items includes updates regarding sickle cell therapies (e.g,, Pfizer’s withdrawal of Oxbryta and Vertex’s choosing of Lonza as the commercial manufacturer of Casgevy); Emergent BioSolutions $400 million BARDA contract for an mpox vaccine; and the first in a generation novel schizophrenia drug, Cobenfy (xanomeline and trospium chloride).
Pharma Marketing Network
OCTOBER 3, 2024
In the competitive landscape of the pharmaceutical industry, effective marketing strategies are crucial for brand success. Pharmaceutical marketing is not just about reaching healthcare professionals and patients; it involves a complex interplay of understanding market dynamics, regulatory compliance, and leveraging digital platforms. This article explores key strategies for promoting pharmaceutical brands, providing insights into understanding market dynamics, identifying target audiences, craf
PharmaTech
OCTOBER 3, 2024
The stand at booth 4A41, carried over from last year in Barcelona, will be constructed of white honeycomb cardboard and linoleum, with material waste generated during production repurposed into seats and tables.
Advertisement
Are your sellers unsure about using AI in their day-to-day workflows? Or are they eager to try but uncertain where to start? They might be asking: Which tasks are best suited for AI? How will using AI affect my relationship with my customers? With so many tools available, which ones are the most useful to me? To help answer these and other common questions about using AI during the sales cycle, we surveyed B2B sellers who were early adopters to get their insight and advice about how to use gen A
Pharma Marketing Network
OCTOBER 3, 2024
In the rapidly evolving landscape of pharmaceutical marketing, Pay-Per-Click (PPC) advertising has emerged as a pivotal tool for reaching targeted audiences efficiently. However, the success of PPC campaigns hinges not just on their execution but also on the robust analysis of their performance. Understanding PPC analytics in the context of pharma marketing is crucial for optimizing campaigns and ensuring a high return on investment.
PharmExec
OCTOBER 3, 2024
Priority Review was based on data from the ECHO Phase III trial, which demonstrated that a combination of Calquence, bendamustine, and rituximab reduced the risk of disease progression or death by 27% in patients with previously untreated mantle cell lymphoma.
PharmaTech
OCTOBER 3, 2024
Pharmaceutical Technology sat down with Erica Schlesinger, vice president of technical development at Serán Bioscience, to talk about her upcoming presentation at AAPS PharmSci 360 2024, “High Dose Subcutaneous Delivery of Protein Therapeutics.
Evolve Your Success
OCTOBER 3, 2024
From a potential future orthopedic surgeon to a passionate advocate for medical sales professionals, this episode is my personal narrative laid bare. During my college days at UC Riverside, shadowing doctors made me realize surgery wasn’t my calling, leading me to a research job that ultimately opened the door to an entirely new world. Listen as I recount the decisions that set me on a transformative journey into medical sales.
Pharmaceutical Commerce
OCTOBER 3, 2024
In this video interview with Pharma Commerce Editor Nicholas Saraceno, Jenni Zilka, SVP, community & specialty pharmacy and president, Good Neighbor Pharmacy, clarifies the meaning behind pharmacy deserts, along with reasons for their increase in prominence.
European Pharmaceutical Review
OCTOBER 3, 2024
What are the greatest challenges in getting AAV-based gene therapies to clinic, and how can the industry work together to overcome them? A common challenge cited by developers of AAV therapies is the difficulty of scaling up production. Production processes established during small-scale preclinical production often require significant modification to meet the demands of clinical scales, which necessitate the production of larger volumes of material in order to dose more patients.
Pharmaceutical Technology
OCTOBER 3, 2024
Gilead Sciences has announced the signing of voluntary licencing agreements with six generic pharmaceutical manufacturers to facilitate access to lenacapavir, a potential human immunodeficiency virus (HIV) prevention drug, in 120 resource-limited and high-incidence nations.
European Pharmaceutical Review
OCTOBER 3, 2024
While it officially applies to the manufacture of sterile medicinal products in the European Union, the revised EU Good Manufacturing Practice (GMP) Annex 1 effectively reset the benchmark for quality standards across the globe on 25 August 2023. At this point, entire supply chains entered a new era defined by a raft of updated rules, all of which are ultimately focused on enhancing levels of public health protection.
Advertisement
Clinical research has entered a new era, one that requires real-time analytics and visualization to allow trial leaders to work collaboratively and to develop, at the click of a mouse, deep insights that enable proactive study management. Learn how Revvity Signals helps drug developers deliver clinical trial data insights in real-time using a fast and flexible data and analytics platform to empower data-driven decision-making.
Expert insights. Personalized for you.
287 
Let's personalize your content